Von Hippel-Lindau status influences phenotype of liver cancers arising from PTen loss

Background: PTEN loss contributes to the development of liver diseases including hepatic steatosis and both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). The factors that influence the penetrance of these conditions are unclear. We explored the influence of sus-tained hypoxia signaling through co-deletion of Pten and Vhl in a murine model. Methods: We used a CreER-linked Keratin 18 mouse model to conditionally delete Pten , Vhl or both in somatic cells of adult mice, evaluating the resultant tumors by histology and gene expression microarray. Existing sets of gene expression data for human HCC and CC were examined for pathways related to those observed in the murine tumors, and a cohort of human CC samples was evaluated for relationships between HIF-1 α expression and clinical outcomes. Results: Both Pten deletion genotypes developed liver tumors, but with differing phenotypes. Pten deletion alone led to large hepatic tumors with widespread hepatosteatosis. Co-deletion of Pten and Vhl with the Keratin 18 promoter resulted in reduced steatosis and a reduced tumor burden that was characterized by a trabecular architecture similar to CC. Genes associated with hepatic steatosis were coordinately expressed in the human HCC dataset, while genes involved in hypoxia response were upregulated in tumors from the human CC dataset. HIF-1 α expression and overall survival were examined in an independent cohort of human CC tumors with no statistical differences uncovered. Conclusion: Pten deletion in Keratin 18 expressing cells leads to aggressive tumor formation and widespread steatosis in mouse livers. Co-deletion of Vhl and Pten results in lower tumor burden with gene expression profiling suggesting a switch from a profile of lipid deposition to an expression profile more consistent with upregulation of the hypoxia response pathway. A relationship between tumor hypoxia signaling and altered hepatic steatotic response suggests that competing influences may alter tumor phenotypes.

[1]  W. Sung,et al.  Genomic portrait of resectable hepatocellular carcinomas: Implications of RB1 and FGF19 aberrations for patient stratification , 2014, Hepatology.

[2]  Hyo Joon Kim,et al.  HIF‐1α Expression as a Protective Strategy of HepG2 Cells Against Fatty Acid‐Induced Toxicity , 2014, Journal of Cellular Biochemistry.

[3]  W. Gong,et al.  Effects of AFP-activated PI3K/Akt signaling pathway on cell proliferation of liver cancer , 2014, Tumor Biology.

[4]  Swe Swe Myint,et al.  Exome sequencing identifies distinct mutational patterns in liver fluke–related and non-infection-related bile duct cancers , 2013, Nature Genetics.

[5]  G. Riggins,et al.  Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy , 2013, Tumor Biology.

[6]  Ze-Guang Han,et al.  SRPK1 contributes to malignancy of hepatocellular carcinoma through a possible mechanism involving PI3K/Akt , 2013, Molecular and Cellular Biochemistry.

[7]  M. Akyildiz,et al.  The Predictive and Prognostic Significance of c-erb-B2, EGFR, PTEN, mTOR, PI3K, p27, and ERCC1 Expression in Hepatocellular Carcinoma , 2012, Hepatitis monthly.

[8]  M. Suematsu,et al.  HIF-1α induction suppresses excessive lipid accumulation in alcoholic fatty liver in mice. , 2012, Journal of hepatology.

[9]  T. Utsunomiya,et al.  Hypoxia inducible factor expression in intrahepatic cholangiocarcinoma. , 2011, Hepato-gastroenterology.

[10]  Rameen Beroukhim,et al.  Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene. , 2011, Cancer discovery.

[11]  D. Jain,et al.  Molecular Pathology of Hepatic Neoplasms: Classification and Clinical Significance , 2011, Pathology research international.

[12]  J. Burnett,et al.  Genetic determinants of hepatic steatosis in man , 2011, Journal of Lipid Research.

[13]  Jung-Hwan Yoon,et al.  Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. , 2010, Cancer research.

[14]  W. Rathmell,et al.  VHL and PTEN loss coordinate to promote mouse liver vascular lesions , 2010, Angiogenesis.

[15]  Y. Morine,et al.  Expression of hypoxia-inducible factor-1 alpha (HIF-1α) in patients with the gallbladder carcinoma , 2010, International Journal of Clinical Oncology.

[16]  E. Noone,et al.  Microarray analysis of hepatic gene expression identifies new genes involved in steatotic liver , 2009, Physiological genomics.

[17]  Seung‐Mo Hong,et al.  The Expression of Phospho-AKT, Phospho-mTOR, and PTEN in Extrahepatic Cholangiocarcinoma , 2009, Clinical Cancer Research.

[18]  Brian Keith,et al.  HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. , 2008, Cancer cell.

[19]  A. Suzuki,et al.  Phosphatase and tensin homolog (PTEN) regulates hepatic lipogenesis, microsomal triglyceride transfer protein, and the secretion of apolipoprotein B–containing lipoproteins , 2008, Hepatology.

[20]  T. Yoshizumi,et al.  Expression of Hypoxia-Inducible Factor-1&agr;, Histone Deacetylase 1, and Metastasis-Associated Protein 1 in Pancreatic Carcinoma: Correlation With Poor Prognosis With Possible Regulation , 2008, Pancreas.

[21]  A. Hamsten,et al.  Genes Involved in Fatty Acid Partitioning and Binding, Lipolysis, Monocyte/Macrophage Recruitment, and Inflammation Are Overexpressed in the Human Fatty Liver of Insulin-Resistant Subjects , 2007, Diabetes.

[22]  T. Gruenberger,et al.  Activated Mammalian Target of Rapamycin Is an Adverse Prognostic Factor in Patients with Biliary Tract Adenocarcinoma , 2007, Clinical Cancer Research.

[23]  T. Khoury,et al.  Akt expression may predict favorable prognosis in cholangiocarcinoma , 2006, Journal of gastroenterology and hepatology.

[24]  G. Gores,et al.  Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. , 2006, The Journal of clinical investigation.

[25]  S. Dudoit,et al.  Exploration of global gene expression in human liver steatosis by high-density oligonucleotide microarray , 2006, Laboratory Investigation.

[26]  C. Pairojkul,et al.  Nitrative and oxidative DNA damage in intrahepatic cholangiocarcinoma patients in relation to tumor invasion. , 2005, World journal of gastroenterology.

[27]  J. Zucman‐Rossi,et al.  Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas. , 2004, Journal of hepatology.

[28]  P. Pandolfi,et al.  Pten Dose Dictates Cancer Progression in the Prostate , 2003, PLoS biology.

[29]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[30]  H. Hanafusa,et al.  PTEN Induces Cell Cycle Arrest by Decreasing the Level and Nuclear Localization of Cyclin D1 , 2003, Molecular and Cellular Biology.

[31]  P. Chambon,et al.  Expression of conditional cre recombinase in epithelial tissues of transgenic mice , 2003, Genesis.

[32]  J. Gnarra,et al.  Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. , 2003, Cancer cell.

[33]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[34]  R. Jaenisch,et al.  Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[35]  J. Zucman‐Rossi,et al.  Genetics of hepatocellular carcinoma: the next generation. , 2014, Journal of hepatology.